Services-Medical Laboratories · DE · CIK 1603454
Celcuity Inc. develops targeted therapies for solid tumors, focusing on its lead candidate gedatolisib
Comparable business profile · signals at a glance
Coverage (30d): 1 reputable article · skews ▲ positive.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
In the 90 days to Jan 27, 2026: 2 sold $4.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 27, 2026 | Dalvey DavidDirector | Sell | 20,000 | $120.03 | $2.4M |
| Dec 5, 2025 | Buller Richard EDirector | Sell | 1,510 | $106.04 | $160K |
| Dec 5, 2025 | Buller Richard EDirector | Sell | 1,490 | $105.34 | $157K |
| Dec 1, 2025 | Buller Richard EDirector | Sell | 1,100 | $98.13 | $108K |
| Nov 21, 2025 | Dalvey DavidDirector | Sell | 15,000 | $100.00 | $1.5M |
| Nov 20, 2025 | Buller Richard EDirector | Sell | 3,900 | $96.73 | $377K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.